Healthcare provider profile · identity verified

Yang Bai, M.D.

Internal Medicine · WOODLAND HILLS, CA · NPI 1710319546

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	696	263
Losartan Potassium	Losartan Potassium	385	141
Rosuvastatin Calcium	Rosuvastatin Calcium	381	147
Amlodipine Besylate	Amlodipine Besylate	351	138
Lisinopril	Lisinopril	305	115
Levothyroxine Sodium	Levothyroxine Sodium	228	90
Meloxicam	Meloxicam	179	90
Tamsulosin Hcl	Tamsulosin Hcl	174	69
Alendronate Sodium	Alendronate Sodium	170	64
Simvastatin	Simvastatin	168	68
Metformin Hcl	Metformin Hcl	156	58
Atenolol	Atenolol	149	66
Omeprazole	Omeprazole	149	77
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	134	42
Metformin Hcl Er	Metformin Hcl	121	44
Gabapentin	Gabapentin	106	51
Furosemide	Furosemide	101	42
Triamcinolone Acetonide	Triamcinolone Acetonide	99	61
Pradaxa	Dabigatran Etexilate Mesylate	98	38
Glipizide	Glipizide	90	38
Hydrochlorothiazide	Hydrochlorothiazide	90	35
Metoprolol Tartrate	Metoprolol Tartrate	89	34
Albuterol Sulfate Hfa	Albuterol Sulfate	88	61
Pantoprazole Sodium	Pantoprazole Sodium	86	35
Trazodone Hcl	Trazodone Hcl	84	32
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	82	32
Finasteride	Finasteride	81	29
Tramadol Hcl	Tramadol Hcl	79	24
Clopidogrel	Clopidogrel Bisulfate	70	28
Terazosin Hcl	Terazosin Hcl	69	26
Potassium Chloride	Potassium Chloride	67	34
Fluoxetine Hcl	Fluoxetine Hcl	62	19
Fluticasone Propionate	Fluticasone Propionate	61	18
Allopurinol	Allopurinol	51	19
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	51	16
Spironolactone	Spironolactone	51	21
Jardiance	Empagliflozin	48	21
Prednisone	Prednisone	47	40
Carvedilol	Carvedilol	46	18
Ezetimibe	Ezetimibe	44	16
Sertraline Hcl	Sertraline Hcl	44	17
Pravastatin Sodium	Pravastatin Sodium	43	21
Hydrocortisone	Hydrocortisone	41	25
Escitalopram Oxalate	Escitalopram Oxalate	35	16
Propranolol Hcl	Propranolol Hcl	35	13
Famotidine	Famotidine	34	18
Lactulose	Lactulose	33	17
Estradiol	Estradiol	31	12
Hydralazine Hcl	Hydralazine Hcl	31	11
Ketoconazole	Ketoconazole	31	14
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	31	11
Warfarin Sodium	Warfarin Sodium	31	suppressed
Clonazepam	Clonazepam	30	suppressed
Montelukast Sodium	Montelukast Sodium	30	12
Ondansetron Odt	Ondansetron	29	12
Acetaminophen-Codeine	Acetaminophen With Codeine	27	suppressed
Bupropion Xl	Bupropion Hcl	27	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	27	11
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	26	26
Colchicine	Colchicine	26	11
Azelastine Hcl	Azelastine Hcl	25	suppressed
Bupropion Hcl Sr	Bupropion Hcl	25	14
Ciclopirox	Ciclopirox	25	13
Cefadroxil	Cefadroxil	24	22
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	24	suppressed
Ibuprofen	Ibuprofen	24	13
Ondansetron Hcl	Ondansetron Hcl	24	suppressed
Tizanidine Hcl	Tizanidine Hcl	24	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	23	12
Duloxetine Hcl	Duloxetine Hcl	22	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	22	suppressed
Valacyclovir	Valacyclovir Hcl	22	13
Arexvy	Rsvpref3 Antigen/As01e/Pf	21	21
Bisoprolol Fumarate	Bisoprolol Fumarate	21	suppressed
Clobetasol Propionate	Clobetasol Propionate	21	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	20	suppressed
Mirtazapine	Mirtazapine	20	12
Mupirocin	Mupirocin	20	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	20	suppressed
Naproxen	Naproxen	19	suppressed
Ozempic	Semaglutide	19	suppressed
Spiriva Respimat	Tiotropium Bromide	19	suppressed
Xarelto	Rivaroxaban	19	suppressed
Alvesco	Ciclesonide	18	12
Benazepril Hcl	Benazepril Hcl	18	suppressed
Nifedipine Er	Nifedipine	18	suppressed
Trospium Chloride	Trospium Chloride	18	suppressed
Betamethasone Diprop Augmented	Betamethasone/Propylene Glyc	17	suppressed
Citalopram Hbr	Citalopram Hydrobromide	17	suppressed
Digoxin	Digoxin	17	suppressed
Eliquis	Apixaban	17	suppressed
Erythromycin	Erythromycin Base	17	13
Lorazepam	Lorazepam	17	14
Metoprolol Succinate	Metoprolol Succinate	17	suppressed
Metronidazole	Metronidazole	17	suppressed
Nystatin	Nystatin	17	suppressed
Brilinta	Ticagrelor	16	suppressed
Amoxicillin	Amoxicillin	15	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	15	15
Baclofen	Baclofen	15	suppressed
Fluorouracil	Fluorouracil	15	suppressed
Temazepam	Temazepam	15	suppressed
Alprazolam	Alprazolam	14	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	14	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	14	suppressed
Buspirone Hcl	Buspirone Hcl	13	suppressed
Cyclosporine	Cyclosporine	13	suppressed
Ipratropium Bromide	Ipratropium Bromide	13	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	13	suppressed
Valsartan	Valsartan	13	suppressed
Humulin N	Insulin Nph Human Isophane	12	suppressed
Klor-Con 8	Potassium Chloride	12	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	12	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	12	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	12	suppressed
Azithromycin	Azithromycin	11	11
Chlorhexidine Gluconate	Chlorhexidine Gluconate	11	suppressed
Dabigatran Etexilate	Dabigatran Etexilate Mesylate	11	11
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	11	suppressed
Dulera	Mometasone/Formoterol	11	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	11	suppressed
Primidone	Primidone	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error